Denali Therapeutics Inc. (DNLI)


Denali Therapeutics Inc. (DNLI)

$17.79 USD

0.31 (-1.71%)

Updated Aug 23 12:00am

Add DNLI to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 216 in Medical - Pharmaceuticals

See all “A” rated Strong Buy stocks

DNLI Daily Price Range
DNLI 52-Week Price Range

DNLI Stock Chart More Charts


DNLI Price/Volume Stats

Current price $17.79
Prev. close $18.10
Day low $17.70
Day high $18.52
50-day MA $19.86
200-day MA $20.81
52-week high $28.86
52-week low $13.78
Volume 252,200
Avg. volume 359,819
Dividend yield N/A
Market Cap 1.71B

Denali Therapeutics Inc. (DNLI) Company Bio


Denali Therapeutics Inc. engages in discovering and developing therapeutics for neurodegenerative diseases in the United States. The company’s lead LRRK2 product candidates includes the DNL201, a small molecule inhibitor that is in Phase I clinical trials, as well as DNL151, a small molecule inhibitor, which is in preclinical development stage for the treatment of Parkinson’s disease. It is also developing therapeutics for the treatment of Parkinson’s, dementia with Lewy bodies, and multiple system atrophy; amyotrophic lateral sclerosis; and mucopolysaccharidosis type II patients. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was founded in 2013 and is based in South San Francisco, California.





DNLI News Stream


Event/Time News Detail
Loading, please wait...

DNLI Social Stream


Loading social stream, please wait...

View Full DNLI Social Stream

DNLI Returns

1-mo -16.01%
3-mo -13.60%
6-mo -18.80%
1-year 8.28%
3-year N/A
5-year N/A
YTD -13.89%
2018 32.10%
2017 N/A
2016 N/A
2015 N/A
2014 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.4122 seconds.